Rituxumab glomerulonephritis – pro
In patients with steroid-dependent minimal change disease or frequently relapsing disease, and in patients with idiopathic membranous nephropathy (IMN), several retrospective and prospective studies support the use of rituximab to induce remission, whereas in idiopathic focal and segmental glomerulosclerosis (FSGS), the use of rituximab has resulted in variable results. Evidence is still lacking for the use of rituximab in patients with immunoglobulin A nephropathy (IgAN) and idiopathic membranoproliferative glomerulonephritis (MPGN), as only few reports used rituximab in these two entities. several recent trials provided evidence supporting rituximab for of steroid-dependent and frequently relapsing minimal change disease, IMN, both as first-line and second-line treatment, and in MPGN.Ig A, IgG and membranous nephropathy seem to respond to this treatment.
Fabrizi F, Cresseri D, Fogazzi GB, et al. Rituximab therapy for primary glomerulonephritis: Report on two cases. World J Clin Cases. 2015;3(8):736-742. doi:10.12998/wjcc.v3.i8.736
Mallat SG, Itani HS, Abou-Mrad RM, Abou Arkoub R, Tanios BY. Rituximab use in adult primary glomerulopathy: where is the evidence?. Ther Clin Risk Manag. 2016;12:1317-1327. Published 2016 Aug 29. doi:10.2147/TCRM.S114316
Guiard E, Karras A, Plaisier E, Duong Van Huyen JP, Fakhouri F, Rougier JP, Noel LH, Callard P, Delahousse M, Ronco P. Patterns of noncryoglobulinemic glomerulonephritis with monoclonal Ig deposits: correlation with IgG subclass and response to rituximab. Clin J Am Soc Nephrol. 2011 Jul;6(7):1609-16. doi: 10.2215/CJN.10611110. Epub 2011 Jun 23. PMID: 21700823.